Replimune (REPL) Cash & Current Investments (2018 - 2025)

Replimune has disclosed Cash & Current Investments across 8 years of filings, most recently posting $269.1 million for Q4 2025.

• Cash & Current Investments for Q4 2025 came in at $269.1 million, down 49.84% year-over-year; the trailing twelve-month figure through Dec 2025 was $269.1 million (down 49.84% YoY), and the FY2025 annual result was $483.8 million, up 15.01% from the prior year.
• Cash & Current Investments came in at $269.1 million for Q4 2025 at Replimune, down from $323.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $616.4 million in Q4 2022 to a low of $269.1 million in Q4 2025.
• The 5-year median for Cash & Current Investments is $447.1 million (2021), against an average of $446.9 million.
• Across the five-year window, Cash & Current Investments soared 226.76% in 2021 and slumped 49.84% in 2025, its largest moves.
• Replimune's Cash & Current Investments stood at $420.2 million in 2021, then jumped by 46.7% to $616.4 million in 2022, then decreased by 24.34% to $466.4 million in 2023, then advanced by 15.05% to $536.5 million in 2024, then plunged by 49.84% to $269.1 million in 2025.
• The last three Cash & Current Investments figures came in at $269.1 million (Q4 2025), $323.6 million (Q3 2025), and $403.3 million (Q2 2025), per Business Quant data.